Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study

Nashi, Masanori; Hirai, Toshinori; Iwamoto, Takuya; Takenobu, Toshihiko

doi:10.1007/s00774-022-01367-x

Cited by 2 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, BMA administration, with its resultant bone remodeling inhibition, suppression of osteoclast activity, and angiogenesis inhibition combined with the abundance of oral bacteria and easily infected jawbones, is hypothesized to cause ARONJ [20,31]. Nashi et al reported that age and low serum albumin levels were associated with severe ARONJ, re ecting delayed wound healing [32]. The carcinomatous state with a high number of bone metastases is a systemic in ammatory state in which in ammation delays wound healing and increases scar formation [33].…”

Section: Discussionmentioning

confidence: 99%

Cumulative Incidence and Risk Factors for Anti-Resorptive Agent-Related Osteonecrosis of the Jaw during Long-Term Prostate Cancer Management

Tani,

Hatano,

Yoshimura

et al. 2024

Preprint

View full text Add to dashboard Cite

Bone-modifying agents (BMA) are extensively used in treating patients with prostate cancer with bone metastases. However, this increases the risk of anti-resorptive agent-related osteonecrosis of the jaw (ARONJ). The safety of long-term BMA administration in clinical practice remains unclear. We aimed to determine the cumulative incidence and risk factors of ARONJ. One hundred and seventy-nine patients with prostate cancer with bone metastases treated with BMA at our institution since 2008 were included in this study. Twenty-seven patients (15%) had ARONJ during the follow-up period (median, 19 months; interquartile range, 9–43 months). The 2-year, 5-year, and 10-year cumulative ARONJ incidence rates were 18%, 27%, and 61%, respectively. Multivariate analysis identified denosumab use as a risk factor for ARONJ, compared with zoledronic acid use (HR 4.64, 95% CI 1.93–11.1). Additionally, BMA use at longer than one-month intervals was associated with a lower risk of ARONJ (HR 0.08, 95% CI 0.01–0.64). Furthermore, six or more bone metastases (HR 3.65, 95% CI 1.13–11.7) and diabetes mellitus (HR 5.07, 95% CI 1.68–15.2) were risk factors for stage 2 or more severe ARONJ. ARONJ should be considered during long-term BMA administration in prostate cancer patients with bone metastases.

show abstract

Section: Discussionmentioning

confidence: 99%

Cumulative Incidence and Risk Factors for Anti-Resorptive Agent-Related Osteonecrosis of the Jaw during Long-Term Prostate Cancer Management

Tani,

Hatano,

Yoshimura

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Furthermore, BMA administration, with its resultant bone remodeling inhibition, suppression of osteoclast activity, and angiogenesis inhibition combined with the abundance of oral bacteria and easily infected jawbones, is hypothesized to cause MRONJ 22 , 35 . Nashi et al reported that age and low serum albumin levels were associated with severe MRONJ, reflecting delayed wound healing 36 . The carcinomatous state with a high number of bone metastases is a systemic inflammatory state in which inflammation delays wound healing and increases scar formation 37 .…”

Section: Discussionmentioning

confidence: 99%

Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management

Tani,

Hatano,

Yoshimura

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Bone-modifying agents (BMA) are extensively used in treating patients with prostate cancer with bone metastases. However, this increases the risk of medication-related osteonecrosis of the jaw (MRONJ). The safety of long-term BMA administration in clinical practice remains unclear. We aimed to determine the cumulative incidence and risk factors of MRONJ. One hundred and seventy-nine patients with prostate cancer with bone metastases treated with BMA at our institution since 2008 were included in this study. Twenty-seven patients (15%) had MRONJ during the follow-up period (median, 19 months; interquartile range, 9–43 months). The 2-year, 5-year, and 10-year cumulative MRONJ incidence rates were 18%, 27%, and 61%, respectively. Multivariate analysis identified denosumab use as a risk factor for MRONJ, compared with zoledronic acid use (HR 4.64, 95% CI 1.93–11.1). Additionally, BMA use at longer than one-month intervals was associated with a lower risk of MRONJ (HR 0.08, 95% CI 0.01–0.64). Furthermore, six or more bone metastases (HR 3.65, 95% CI 1.13–11.7) and diabetes mellitus (HR 5.07, 95% CI 1.68–15.2) were risk factors for stage 2 or more severe MRONJ. MRONJ should be considered during long-term BMA administration in prostate cancer patients with bone metastases.

show abstract

Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study

Cited by 2 publications

References 28 publications

Cumulative Incidence and Risk Factors for Anti-Resorptive Agent-Related Osteonecrosis of the Jaw during Long-Term Prostate Cancer Management

Cumulative Incidence and Risk Factors for Anti-Resorptive Agent-Related Osteonecrosis of the Jaw during Long-Term Prostate Cancer Management

Cumulative incidence and risk factors for medication-related osteonecrosis of the jaw during long-term prostate cancer management

Contact Info

Product

Resources

About